<DOC>
	<DOCNO>NCT02423954</DOCNO>
	<brief_summary>Determine recommend phase 2 dose ( RP2D ) chemotherapy combination nivolumab subject advance cancer .</brief_summary>
	<brief_title>Study Nivolumab Plus Chemotherapy Patients With Advanced Cancer ( NivoPlus )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Phase Ib II : 1 . Patient least 18 year old definitive histologically cytologically confirm metastatic solid tumor . 2 . Patient one metastatic tumor measurable CT scan ( PET/CT , patient allergic CT contrast medium ) . Tumor site consider measureable must receive prior radiation therapy . For metastatic tumor measurable CT and/or PET/CT , need tumor measure least 1cm one dimension digital caliper physical exam . 3 . Patients enrol one treatment arm trial . 4 . The investigator select appropriate treatment arm patient follow requirement : ( ) Patients prior progression intolerance single agent chemotherapy enrol arm single agent chemotherapy plus nivolumab ( b ) The chemotherapy arm select must consider standard care component list NCCN guideline ( www.nccn.org ) cancer type . 5 . Have recover acute toxicity prior treatment : &gt; 3 week must elapse since receive investigational agent . &gt; 2 week must elapse since receive radiotherapy , ≥ 3 week 5 halflives whichever shorter treatment cytotoxic biologic agent ( ≥ 6 week mitomycin nitrosoureas ) . Chronic treatment noninvestigational gonadotropinreleasing hormone analog hormonal supportive care permit . 6 . Patient adequate biological parameter demonstrate follow blood count time screening : 7 . Absolute neutrophil count ( ANC ) &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 9 g/dL . Subject give pack red blood cell transfusion 8 . Calculated creatinine clearance &gt; 40 ml/min CockroftGault equation : [ CreatClear = Sex * ( ( 140 Age ) / ( SerumCreat ) ) * ( Weight / 72 ) ; Sex = 1 men 0.85 woman ] , total bilirubin 1.5 time upper limit normal ( ULN ) range , AST/ALT ≤ 3 time upper limit normal ( ULN ) range . 9 . Thyroid stimulate hormone ( TSH ) within institutional normal limit . If TSH upper limit normal range , free T4 within institutional normal limit acceptable . If thyroid replacement therapy initiate patient may screen enrolled criterion meet . 10 . Persistent prior systemic therapy nonhematologic AE grade ≤ 2 ( except alopecia correctable electrolyte abnormality supplementation ) 11 . Patient Karnofsky performance status ( KPS ) ≥ 70 . 12 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 5 month follow last dose nivolumab 30 day follow last dose chemotherapy trial trial , must negative urine serum pregnancy test within 2 week prior begin treatment trial . If female subject female partner male subject become pregnant period patient recommend seek appropriate obstetric care . The study monitoring subject female partner subject pregnancy last dose study drug chemotherapy . Exclusion Criteria Phase Ib II : 1 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 2 . Serious nonhealing wound , ulcer , bone fracture . 3 . Patient known brain metastasis . Baseline image brain require within 28 day prior randomization . 4 . Prior therapy mammalian target rapamycin ( mTOR ) inhibitor RCC subject , prior therapy irinotecan topotecan NSCLC subject , prior therapy irinotecan CRC patient . 5 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 6 . Patient know active infection HIV , hepatitis B , hepatitis C ( patient NOT require test presence virus prior therapy protocol ) . 7 . Requiring daily corticosteroid dose ≥ 10 mg prednisone equivalent per day . 8 . Patient undergone major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 9 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 10 . Patient receive anticancer therapy participation trial . 11 . Prior treatment nivolumab allow . Prior receipt PD1 inhibitor PDL1 inhibitor allow . 12 . Active prior document autoimmune disease require systemic treatment within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>